Vedolizumab takes a gut-selective approach that sets it apart from the systemic TNF-inhibitors and other biologics in our immunotherapy catalogue — rather than suppressing immune activity throughout the entire body, it specifically blocks immune cells from migrating into the gastrointestinal tract, which gives it a genuinely more favorable systemic side-effect profile and makes it a preferred option for gastroenterologists managing inflammatory bowel disease in patients where broader immunosuppression carries additional risk.
- Approved indications: Moderate-to-severe ulcerative colitis, Crohn's disease, chronic pouchitis (in adults who haven't responded adequately to conventional therapy)
- Mechanism: Blocks the α4β7 integrin, an adhesion molecule that immune cells use to migrate specifically into gut tissue — inhibiting inflammation locally rather than suppressing immunity systemically
- Typical treatment course: Full response can take up to 14 weeks to become apparent, particularly in more severe Crohn's disease cases, an important expectation-setting point for prescribing physicians
- Long-term therapy: Treatment is generally reviewed every 12 months to confirm continued benefit, with many patients remaining on it for extended periods
- Contraindications: Under 18 years of age; known allergy to vedolizumab or its components; active severe infection (TB, sepsis, severe gastroenteritis, nervous system infection)
- Drug interaction caution: Should not be combined with other immunosuppressive biologics such as natalizumab or rituximab
- Liver risk: Can cause significant liver injury in rare cases, potentially requiring liver transplant — contraindicated in patients with severe liver disorder or jaundice
- PML risk: Rare but serious risk of progressive multifocal leukoencephalopathy — patients and physicians should be alert to neurological symptoms (blurred vision, speech difficulty, limb weakness, gait changes)
- Vaccination: May affect vaccine response — inform physician of planned or recent vaccinations
- Contraception requirement: Required during treatment and for a minimum of 4.5 months after the final dose
- Certification: WHO-GMP sourced manufacturing partners
- Batch-specific testing: α4β7 integrin binding potency validated per batch
- Gastroenterology positioning: We position Vedolizumab as the preferred gut-selective option for distributors serving gastroenterology-focused hospitals and clinics, distinct from our systemic TNF-inhibitor lines
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global export markets
- Tracking: Full shipment tracking included
- Institutional buyers: Hospital and gastroenterology-center procurement support
- Unregistered markets: Named-patient supply pathway available
- Portfolio positioning: A meaningful complement to Infliximab and Adalimumab for gastroenterology distributors wanting a gut-selective option for patients where systemic immunosuppression is a concern
What is Vedolizumab used for?
Treats moderate-to-severe ulcerative colitis, Crohn's disease, and chronic pouchitis.
Get Vedolizumab price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
How is it different from other biologics for Crohn's disease?
It works specifically in the gut rather than suppressing immunity throughout the whole body, giving it a more favorable systemic safety profile.
How long does it take to work?
Full effect can take up to 14 weeks in some patients, particularly in more severe Crohn's disease.
Who supplies Vedolizumab from India?
WHO-GMP certified manufacturing partners with full export documentation.
